By Erfan Akbraian, Analyst Email: [email protected] France’s National Agency for the Safety of Medicines and Health Products (ANSM)1 governs the early access program called autorisation
By Max Rex, Associate Consultant Email: [email protected] Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green
By Nicola Allen, Associate Director Email: [email protected] The priorities of health technology assessment (HTA) bodies are evolving as health care systems around the world are
By Erfan Akbraian, Analyst Email: [email protected] Majority of orphan drug manufacturers do not currently view Israel as an early launch opportunity. However, universal reimbursed access
By Joanna Fernandes, Associate Consultant Email: [email protected] Cell and gene therapies (CGTs) are considered one-time transformative treatments, positioned as having life-long benefits. These new therapies
By Max Rex, Senior Analyst Email: [email protected] Jacob Rees-Mogg, Member of Parliament (MP) for North East Somerset on one of his last days as a
By Ciaran Cassidy, Analyst Email: [email protected] Novartis recently announced an innovative reimbursement scheme with the GWQ – (a body representing a small number of insurance
By Nader Murad, Associate Consultant Email: [email protected] At JPMorgan’s 37th Healthcare Conference in 2019, bluebird bio provided its strategic outlook and plans for the year
By Jack Rawson, Analyst Email: [email protected] Road to commercialization of Vertex’s CF portfolio The European Commission recently approved Vertex’s combination regimen Symkevi (tezacaftor / ivacaftor;
